ALSO NOTED: Light Sciences withdraws IPO; Medicare to restrict anemia meds?; and much more...

> Light Sciences Oncology has withdrawn its IPO registration, citing "unfavorable market conditions." Report

> A Medicare official says there's an even better case now for restricting payments for Amgen and Johnson & Johnson's big anemia drugs. According to the agency's chief medical officer, more studies have cast doubt on the safety of Aranesp, Epogen, and Procrit, which together generated more than $5 billion in sales in 2007. The drugs are one of the biggest prescription costs for Medicare. Report

> Back off, Seroquel imitators. So says AstraZeneca, which is pursuing a summary judgment in its patent fight with Teva Pharmaceutical Industries. Teva has threatened to launch a copycat version of the antipsychotic med as early as next month. Report

> The watchdogs are circling DTC drug commercials. Report

> Check out this list of the most-visited drug websites. Report

And Finally... Even de-fanged botulinum toxin may still be toxic to some people. The FDA says Botox and its sister med Myobloc have been linked to serious reactions, including death. Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.